Cost ‐effectiveness analyses of anti‐hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan

AimWe estimated the cost‐effectiveness of direct‐acting antiviral treatment (DAA) compared to triple therapy (simeprevir, pegylated interferon‐α [Peg‐IFN], and ribavirin [RBV]) (scenario 1), Peg‐IFN + RBV (scenario 2), and non‐antiviral therapy (scenario 3). MethodsCost‐effectiveness was evaluated as incremental cost‐effectiveness ratios (ICERs) using direct costs and indirect costs, which included loss of wages during the patient's lifetime due to early death caused by viral hepatitis infection. Quality of life (QOL) scores were determined by EQ‐5D‐3L questionnaire survey on 200 HCV patients in Hiroshima. ResultsThe QOL scores for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma were estimated as 0.871, 0.774, and 0.780, respectively. The follow‐up period that the ICER of scenario 1 becomes shortest (cost
Source: Hepatology Research - Category: Internal Medicine Authors: Tags: Original Article Source Type: research

Related Links:

Hepatitis C virus (HCV) is a major cause of liver disease including metabolic disease, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). HCV induces and promotes liver disease progression by perturbing a range of survival, proliferative, and metabolic pathways within the proinflammatory cellular microenvironment. The recent breakthrough in antiviral therapy using direct-acting antivirals (DAAs) can cure>90% of HCV patients. However, viral cure cannot fully eliminate the HCC risk, especially in patients with advanced liver disease or comorbidities. HCV induces an epigenetic viral footprint that promotes a pro-onco...
Source: Cold Spring Harbor perspectives in medicine - Category: Research Authors: Tags: Hepatitis C Viruses: The Story of a Scientific and Therapeutic Revolution PERSPECTIVES Source Type: research
Publication date: Available online 17 December 2019Source: Antiviral ResearchAuthor(s): Hee Sun Kim, Youngsu You, Jae Gon Mun, Changdev G. Gadhe, Heejo Moon, Jae Seung Lee, Ae Nim Pae, Michinori Kohara, Gyochang Keum, Byeong Moon Kim, Sung Key JangAbstractApproximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths annually. Effective direct-acting antiviral agents (DAAs) have been developed and are currently used for HCV treatment tar...
Source: Antiviral Therapy - Category: Virology Source Type: research
virus (HCV) is a major public health problem and a leading cause of chronic liver disease. Over 150 million people worldwide have chronic HCV infection and are at risk of developing its life-threatening complications. Acute infection is usually asymptomatic, with most patients unaware that they have contracted the virus. Some patients clear the virus spontaneously, but most become chronic carriers. If carriers are identified, they can be treated with antiviral therapy, the main goal being prevention of cirrhosis, liver failure and hepatocellular carcinoma by eradicating the virus.
Source: Medicine - Category: Internal Medicine Authors: Tags: Liver infections Source Type: research
In this study, we assessed the impact of DAA on liver transplant indications in the UK and waiting list outcomes for patients with HCV. We as sessed UK adult elective liver transplant registrants between 2006 and 2017. The aetiology of liver disease at registration was reclassified using an accepted hierarchical system and changes were assessed over time and compared before and after the introduction of DAA. Registration UKELD scores and 1‐year waiting list outcomes were also compared. The proportion of waiting list patients registered with HCV‐related cirrhosis reduced after the introduction of DAA from 10.5% in 2013 ...
Source: Journal of Viral Hepatitis - Category: Infectious Diseases Authors: Tags: ORIGINAL ARTICLE Source Type: research
Chronic hepatitis C virus (HCV) is associated with substantial morbidity and mortality, with> 71 million people infected worldwide in 2015 [1]. In 2013, an estimated 700,000 deaths globally were attributed to HCV-related liver disease sequelae, namely cirrhosis and hepatocellular carcinoma [2]. Mortality is expected to increase as many individuals infected with HCV decades ago are aging and at high risk of chronic liver disease [3,4]. With the introduction of highly effective and well-tolerated, all-oral direct-acting antiviral (DAA) therapies to treat chronic HCV infection[5,6], there has been renewed optimism regardin...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Publication date: December 2011Source: Digestive and Liver Disease Supplements, Volume 5, Issue 1Author(s): Marina BerenguerAbstractCirrhosis with/without hepatocellular carcinoma is the primary indication for liver transplantation (LT) in many countries. Hepatitis C virus (HCV) reinfection occurs universally resulting in HCV-graft disease with progression to cirrhosis in about one third of cases after 5 years. Graft failure secondary to recurrent HCV is now the most frequent cause of death, graft failure and need for retransplantation in these patients, with a cumulative risk of allograft failure due to recurrent disease ...
Source: Digestive and Liver Disease Supplements - Category: Gastroenterology Source Type: research
AbstractAssessing liver fibrosis is important for predicting the efficacy of antiviral therapy and patient prognosis. Liver biopsy is the gold standard for diagnosing liver fibrosis, despite its invasiveness and problematic diagnostic accuracy. Although noninvasive techniques to assess liver fibrosis are becoming important, reliable serum surrogate markers are not available. A glycoproteomics study aimed at identifying such markers discovered Mac 2-Binding Protein Gylcan Isomer (M2BPGi), which is a reliable marker for assessing liver fibrosis in patients with viral hepatitis and other fibrotic liver diseases such as primar...
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
ConclusionsIFN‐free direct‐acting antiviral therapy of chronic hepatitis C does not alter the short‐term risk for HCC in patients with liver cirrhosis. A reduced HCC incidence may become evident after more than 1.5 years of follow‐up.
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionIn a real‐world setting, DAAs are safe and effective in older adults with HCV‐related advanced fibrosis or cirrhosis. Individuals with preserved albumin synthesis and fewer than 3 comorbidities at baseline have the most to gain from long‐term DAA therapy.
Source: Journal of the American Geriatrics Society - Category: Geriatrics Authors: Tags: Clinical Investigation Source Type: research
Direct‐acting antiviral (DAA) therapy, recently approved for patients with decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hepatic function. We analyzed trends in liver transplant (LT) wait‐listing (WL) to explore potential impact of effective medical therapy on WL registration. This is a cohort study using the Scientific Registry of Transplant Recipients database from 2003 to 2015. A total of 47,591 adults wait‐listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic steatohepatitis (NASH) were identified. LT indication was defined as DC if the Model for End‐...
Source: Hepatology - Category: Internal Medicine Authors: Tags: Viral Hepatitis Source Type: research
More News: Antiviral Therapy | Cancer & Oncology | Carcinoma | Cirrhosis | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Internal Medicine | Japan Health | Liver | Liver Cancer | Liver Disease | Salaries | Urology & Nephrology | Virology | Women